Lead
Weight-loss injections that mimic the hormone GLP-1 are reshaping how people in the UK spend money across groceries, dining, alcohol, fashion and wellness. New University College London research estimates about 1.6 million people used these jabs in 2024, and many more have said they would consider them. For private users the treatments can cost more than £300 a month, and typical behaviour shifts include smaller portions, fewer takeaways and different leisure choices. Businesses from supermarkets to restaurants and gyms are already adapting to these demand changes.
Key takeaways
- About 1.6 million people in the UK used GLP-1 weight-loss injections in 2024, according to University College London research.
- Private treatment can exceed £300 per month, while some users report paying around £186 monthly for their injections.
- Households with GLP-1 users showed a 15-percentage point drop in alcohol volume purchases in a February 2025 Worldpanel by Numerator study versus a benchmark.
- Supermarkets including The Co-op, Morrisons and Marks & Spencer have launched nutrient-dense ready meals; Ocado introduced a 100g steak option reflecting demand for smaller portions.
- A KAM Insight survey found nearly a third of GLP-1 users go out to eat and drink less often, affecting restaurants and casual dining visits.
- Fashion and second-hand marketplaces may see growth as rapid weight loss forces wardrobe replacements; one user reported replacing clothes after falling from size 18 to size 12.
- Fitness and aesthetic services show rising interest: The Gym Group is training staff to support users, and the British Association of Aesthetic Plastic Surgeons reported an 8% rise in facelifts in 2024.
Background
GLP-1 receptor agonists—commonly called weight-loss jabs—work by mimicking a hormone that helps regulate appetite and blood sugar. Originally developed for diabetes, these medications became widely used off-label or for obesity management, bringing them into mainstream consumer markets in 2023–2024. The UCL estimate that roughly 1.6 million people in the UK used these injections in 2024 reflects rapid uptake and strong consumer interest.
As these treatments reduce appetite and portion size, they interact with existing health and wellness trends, particularly among younger shoppers who already prioritise nutrient density and protein-rich choices. Retailers and hospitality firms have begun to respond with smaller portion sizes, alternative menus and non-alcoholic drinks ranges. At the same time, personal spending patterns shift because some users pay large monthly sums for treatment while cutting back on other discretionary items.
Main event
Supermarkets are introducing products aimed at smaller, more nutrient-dense meals: The Co-op, Morrisons and Marks & Spencer have rolled out ranges of ready meals with higher nutritional value, and Ocado added a 100g steak to meet demand for smaller portions. Shoppers who report eating less, like one user who lost four stone since June, say they are choosing fresher ingredients and protein-focused snacks rather than large ready meals.
Dining out patterns are changing. A KAM Insight survey found nearly a third of GLP-1 users dine out and drink less frequently. Individual users confirm this: a 70-year-old from Cornwall said she used to eat out weekly but has stopped since starting injections, and others report fewer takeaways—though savings on food are often offset by the cost of the injections themselves.
Alcohol purchases have also fallen in some households with GLP-1 users. A Worldpanel by Numerator analysis in February 2025 identified a 15-percentage point reduction in alcohol volume purchases among those households compared with a controlled benchmark, while the British Beer and Pub Association expects record consumption of low- and no-alcohol beer in 2025, at around 200 million pints.
Fashion and personal appearance markets feel the impact: rapid weight loss creates demand for new clothing, underwear and accessories, and drives activity on resale platforms. Beauty, fitness and aesthetic services are seeing increased interest too—gyms are adjusting trainer guidance for members on these drugs, and aesthetic clinics reported an 8% rise in facelifts in 2024, consistent with patterns seen after substantial weight loss.
Analysis & implications
Short-term consumer spending is shifting from large-portion, high-calorie items to fresher, nutrient-dense foods and protein-focused products. Retailers that respond with smaller-portion, higher-nutrient SKUs can capture users who still want quality even as quantity declines. That product shift also creates an opportunity for premium, health-oriented lines and for convenience formats built around smaller servings.
Hospitality faces mixed effects: fewer casual visits and takeaways could reduce revenue for some segments, while fine-dining venues and restaurants offering ‘mindful’ menus may attract diners seeking high-quality, lower-calorie experiences. The Fat Duck’s changed menu that emphasises mindful eating is one example of fine dining adapting to smaller appetites.
Alcohol manufacturers and pubs may see demand fall for full-strength products, boosting low- and no-alcohol segments. If the Worldpanel by Numerator finding is replicated broadly, beverage makers will need to accelerate non-alcoholic innovation and repositioning. Over time this could reshape categories and margins across the drinks market.
Fashion and personal care firms face both challenge and opportunity. Rapid body changes increase demand for new wardrobes and drive resale traffic, while beauty and aesthetic services may capture additional spend. However, the net effect on household budgets is ambiguous: many users pay high monthly treatment costs, which could displace other discretionary spending.
Comparison & data
| Sector | Observed change | Representative figure |
|---|---|---|
| Grocery | Smaller portions, nutrient-dense SKUs | Ocado 100g steak launch |
| Dining out | Fewer casual visits | KAM Insight: ~1/3 of users dine out less |
| Alcohol | Lower volume purchases | Worldpanel by Numerator: −15 pp vs benchmark |
| Fashion | Higher wardrobe replacement & resale | Individual cases of full wardrobe replacement |
| Beauty/fitness | Increased interest in services | BAAPS: +8% facelifts in 2024 |
The table summarises reported changes across sectors. While individual figures—such as the 15-percentage point alcohol drop and the 8% rise in facelifts—are concrete, the broader economic impact depends on how many users remain on treatment long term and how companies scale product responses.
Reactions & quotes
“We are reducing alcohol intake alongside reduced food consumption; customers are more concerned with overall health and holistic well-being.”
The Co-op food trading director, Nicole Tallant (quoted to BBC)
“GLP-1 drugs are changing the culture, adding oxygen to existing health trends.”
Jonny Forsyth, food and drink strategist, Mintel
“We have begun educating our trainers on how best to support members on these treatments.”
Will Orr, chief executive, The Gym Group
Unconfirmed
- Whether the spending shifts observed in early adopters will persist if a large portion of the population uses GLP-1 drugs long term is unknown.
- The causal size of alcohol reduction attributable solely to GLP-1 use versus broader sobriety trends is not fully established.
- How many UK beauty brands will launch dedicated products for GLP-1 users and whether those products will be commercially viable in the UK market remains uncertain.
Bottom line
Weight-loss jabs are already nudging consumer behaviour: food purchases are shifting toward smaller portions and nutrient density, dining-out frequency is falling for some users, alcohol purchases are down in affected households, and fashion and wellness sectors are adapting. These shifts reflect both the biological effects of GLP-1 drugs and their interaction with existing health trends.
For businesses, the near-term priority is to meet changed demand with appropriately sized, higher-nutrient offerings and repositioned services. For policymakers and researchers, the key questions are how durable these consumption changes will be, how they affect inequality in spending (given treatment costs exceed £300 monthly for some private users), and what broader public-health implications follow as usage grows.
Sources
- BBC News — BBC (media report summarising industry and research findings)
- University College London — UCL (research estimate on UK usage, 2024)
- Worldpanel by Numerator — market research (February 2025 alcohol purchase analysis)
- KAM Insight — research consultancy (survey on dining frequency)
- British Association of Aesthetic Plastic Surgeons — professional body (2024 facelift data)